CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home Search
Result Type
Evidence Bundles
Product Line
Body Systems
Disease and Conditions
Target Population
Technologies, Therapies and Systems
Testing and Diagnostics
Publication Date
Clear all filters

Reports

We found 6105 result(s)

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: July 30, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: von Willebrand Factor [recombinant]
Indications: von Willebrand disease, adults, treatment and perioperative management

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: New
Details

emicizumab (Hemlibra)

Last Updated: July 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: emicizumab
Indications: Bleeding prevention, hemophilia A

  • Brand Name: Hemlibra
  • Manufacturer: Hoffmann-La Roche Ltd.
  • Project Number: ST0651-000
  • Project Status: Active
  • Submission Type: New
Details

dapagliflozin (Forxiga )

Last Updated: July 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: dapagliflozin
Indications: Heart failure with reduced ejection fraction

  • Brand Name: Forxiga
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0642-000
  • Project Status: Active
  • Submission Type: New
Details

fremanezumab (Ajovy)

Last Updated: July 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: fremanezumab
Indications: migraine

  • Brand Name: Ajovy
  • Manufacturer: Teva Canada Innovation
  • Project Number: SR0641-000
  • Project Status: Received
  • Submission Type: New
Details

eculizumab (Soliris)

Last Updated: July 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: eculizumab
Indications: Neuromyelitis optica spectrum disorder

  • Brand Name: Soliris
  • Manufacturer: Alexion Pharma Canada Corp.
  • Project Number: SR0640-000
  • Project Status: Active
  • Submission Type: New
Details

onasemnogene abeparvovec (Zolgensma)

Last Updated: July 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: onasemnogene abeparvovec
Indications: Spinal muscular atrophy (SMA), pediatrics

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Active
  • Submission Type: New
Details

budesonide (Jorveza)

Last Updated: July 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: budesonide
Indications: Eosinophilic esophagitis, adults

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc.
  • Project Number: SR0634-000
  • Project Status: Active
  • Submission Type: New
Details

ofatumumab (TBC)

Last Updated: July 27, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: ofatumumab
Indications: Multiple Sclerosis, relapsing

  • Brand Name: TBC
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-0000
  • Project Status: Pending
  • Submission Type: New
Details

nintedanib (Ofev)

Last Updated: July 27, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: nintedanib
Indications: chronic fibrosing interstitial lung diseases

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Received
  • Submission Type: New
Details

vedolizumab (Entyvio)

Last Updated: July 27, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: vedolizumab
Indications: Crohn’s disease

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0647-000
  • Project Status: Received
  • Submission Type: New
Details